---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010399"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:45.416848+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ENDRA CEO Michelon resigns; board member Tokman named acting CEO, new CFO and regulatory head appointed

## Summary
- Francois Michelon stepped down as CEO and board member effective Aug 12, 2024; separation includes 4 months' salary and 12 months' healthcare coverage.
- Alexander Tokman, board member since 2008, appointed acting CEO and Chairman effective Aug 13, 2024; Tokman has 24+ years of commercial leadership and prior GE Healthcare executive experience.
- Ziad Rouag appointed Head of Regulatory and Clinical Affairs; Richard Jacroux appointed CFO; Irina Pestrikova to transition and remain advisor.
- Tokman will focus on regulatory approval and commercial launch of TAEUS system with strict fiscal discipline.
- No disagreement involved in Michelon's resignation; separation agreement includes release of claims and termination of restrictive covenants.

## SEC filing metadata
- accession: 0001654954-24-010399
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424010399/0001654954-24-010399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424010399/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010399
- JSON: https://secwatch.observer/filing/0001654954-24-010399.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010399.txt

## Key facts
- Executive change
  Francois Michelon resigned as Chief Executive Officer and Director at ENDRA Life Sciences Inc..
  - Action: resigned
  - Role: Chief Executive Officer and Director
  source text: Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424010399/0001654954-24-010399-index.htm
- Executive change
  Alexander Tokman was appointed as Acting Chief Executive Officer and Chairman at ENDRA Life Sciences Inc..
  - Action: appointed
  - Role: Acting Chief Executive Officer and Chairman
  source text: Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424010399/0001654954-24-010399-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.